Trial Parameters
Brief Summary
This is a randomized, double-blind, placebo-controlled, dose escalation phase I clinical study to evaluate the safety, tolerability, pharmacokinetics, and the food effect on the pharmacokinetics of HS-10542 in healthy participants.
Eligibility Criteria
Inclusion Criteria： 1. Male or female between 18 and 64 years of age (critical values inclusive) when signing the informed consent form. 2. Body mass index (BMI = weight/height2) ≥ 19 kg/m2 and ≤ 28 kg/m2 at screening, and body weight ≥ 50 kg for men and ≥ 45 kg for women. 3. Physical examination, laboratory tests, 12-lead ECG, abdominal B-ultrasound and anteroposterior and lateral chest X-ray (or CT) examination showed no abnormality, or slight abnormality but with no clinical significance as judged by the investigator, or slight abnormality but with controllable risk as judged by the investigator, and communication with the sponsor 's medical and pharmacological personnel is required when necessary; 4. Female participants are required to agree to practice highly effective contraception from 2 weeks before screening until 60 days after the last dose: 5. Male participants of childbearing potential are required to agree to practice highly effective contraception from the date of signing